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STUDY PROTOCOL Open Access
Study protocol: HepaT1ca – an
observational clinical cohort study to
quantify liver health in surgical candidates
for liver malignancies
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Velicia Bachtiar6, Matt Kelly6*, Stephen J. Wigmore1,2, O. James Garden2, Henry R. Wilman6,7, Rajarshi Banerjee6,
Myrddin Rees4 and Michael Brady6
Abstract
Background: Accurate assessment of liver health prior to undertaking resectional liver surgery or chemoembolisation
for primary and secondary cancers is essential for patient safety and optimal outcomes. LiverMultiScan™, an MRI-based
technology, non-invasively quantifies hepatic fibroinflammatory disease, steatosis and iron content. We hypothesise
that LiverMultiScan™can quantify liver health prior to surgery and inform the risk assessment for patients considering
liver surgery or chemoembolization and seek to evaluate this technology in an operational environment.
Methods/Design: HepaT1ca is an observational cohort study in two tertiary-referral liver surgery centres in the United
Kingdom. The primary outcome is correlation between the pre-operative liver health assessment score (Hepatica score -
calculated by weighting future remnant liver volume by liver inflammation and fibrosis (LIF) score) and the post-operative
liver function composite integer-based risk (Hyder-Pawlik) score.
With ethical approval and fully-informed consent, individuals considering liver surgery for primary or secondary cancer
will undergo clinical assessment, blood sampling, and LiverMultiScan™multiparametric MRI before and after surgical liver
resection or TACE. In nested cohorts of individuals undergoing chemotherapy prior to surgery, or those undergoing
portal vein embolization (PVE) as an adjunct to surgery, an additional testing session prior to commencement of
treatment will occur. Tissue will be examined histologically and by immunohistochemistry. Pre-operative liver health
assessment scores and the post-operative risk scores will be correlated to define the ability of LiverMultiScan™to predict
the risk of post-operative morbidity and mortality. Because technology performance in this setting is unknown, a
pragmatic sample size will be used. For the primary outcome, n = 200 for the main cohort will allow detection of a
minimum correlation coefficient of 0.2 with 5% significance and power of 80%.
Discussion: This study will refine the technology and clinical application of multiparametric MRI (including
LiverMultiScan™), to quantify pre-existing liver health and predict post-intervention outcomes following liver
resection. If successful, this study will advance the technology and support the use of multiparametric MRI as
part of an enhanced pre-operative assessment to improve patient safety and to personalise operative risk
assessment of liver surgery/non-surgical intervention.
Trial registration: This study is registered on ClinicalTrials.gov Identifier: NCT03213314.
* Correspondence: damian.mole@ed.ac.uk; Matt.Kelly@perspectum-
diagnostics.com
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Background
An adequate level of liver function is essential for life.
The liver is unique among the abdominal organs for the
ability to regenerate following partial surgical resection
(hepatectomy). Patients with pre-existing parenchymal
liver disease have impaired liver regeneration and are at
increased risk of postoperative morbidity and mortality
after liver resection [1]. The ability to accurately assess
liver health before surgery is a critical part of judging
the safety of a planned hepatectomy, and is important
for a well-informed discussion of the risks and benefits
with individuals who are considering liver surgery. While
the concept of having adequate liver volume and function is
understood, there is no universally accepted method of func-
tional liver assessment which has been applied to liver sur-
gery. Because of the increased prevalence of non-alcoholic
fatty liver disease (NAFLD) in the general population [2] –
NAFLD now has a global prevalence of 25% [3] – it
is estimated that 1 in 5 patients planned for liver re-
section have some degree of steatosis [4]. Even a mild
degree of fat accumulation in the liver affects hepato-
cyte homeostasis and potentially impairs postoperative
recovery after hepatectomy [5].
Here, we propose that multiparametric MRI including
LiverMultiScan™ is one possible solution to this challenge.
LiverMultiScan™is a non-invasive MRI-based technology
shown to correlate with hepatic fibroinflammatory disease,
steatosis and iron content [6], that can predict outcomes
in patients with chronic liver disease [7]. In this study, we
will use LiverMultiScan™as an additional quantitative
measure of liver health prior to hepatectomy, typically
done for colorectal liver metastases, or transarterial che-
moembolization (TACE), typically done for hepatocellular
carcinoma (HCC). In a small subset of patients in whom
portal vein embolization (PVE) is performed prior to
hepatectomy to promote hypertrophy of the FLR [8, 9], or
in those receiving systemic anti-cancer therapy (chemo-
therapy), an additional pre-operative LiverMultiSca-
n™assessment will be undertaken to detect FLR
hypertrophy and any chemotherapy-associated liver
injury prior to surgery. For patients with HCC, TACE
is usually well-tolerated by people with healthy livers,
but can precipitate liver decompensation in the con-
text of pre-existing chronic liver disease [10]. We
propose that LiverMultiScan™can also quantify liver
health (and therefore risk of liver decompensation)
after TACE.
In summary, this observational clinical cohort study
aims to evaluate the technical utility of multiparametric
MRI including LiverMultiScan™, to quantify pre-existing
liver health and predict post-intervention outcomes fol-
lowing liver resection (with or without pre-operative
chemotherapy or PVE) or TACE. The technology readi-
ness level (TRL) of this study could be regarded as level
7 in the European Union scale, defined as, “system
prototype demonstration in operational environment”
[11]. If successful, this study will assist in refinement of
the technology and provide proof-of-concept for multi-
parametric MRI to be progressed further in techno-
logical evaluation as part of an enhanced pre-operative
assessment in patients to improve patient safety and to
personalise the operative risk assessment of liver sur-
gery/non-surgical intervention.
Methods
Study authorisations
This study has been reviewed as IRAS 223180 by the
South East Scotland Research Ethics Committee 02, 17/
SS/0049 who gave a favourable opinion. NHS Scotland
R&D approval and NHS England HRA approval have
been granted. The study sponsor is University of
Edinburgh/NHS Lothian ACCORD.
Study design
Observational cohort study.
Setting
Two tertiary referral hepatobiliary surgery centres in the
United Kingdom; (Royal Infirmary of Edinburgh and
Basingstoke and North Hampshire Hospital).
Timing
Recruitment is scheduled to begin on 1st August 2017
and continue until 31st January 2019. The general study
outline and timelines are illustrated in Fig. 1.
Intervention
No change in treatment, intervention or randomisation
is proposed in the present study.
Eligible participants who have given informed consent
will be asked to attend the local research facility for an ini-
tial study visit during which baseline clinical assessments,
blood tests, and LiverMultiScan™MR imaging will be
undertaken. Participants in the main study cohort will
attend on a second occasion in the post-operative/post-
TACE period (total 2 visits and scans). For participants who
are enrolled in either of the nested study cohorts (i.e. those
undergoing pre-operative chemotherapy or PVE as an ad-
junct to surgery), an additional scan visit will be required
(total 3 visits and scans). An additional 6-month period will
follow to complete the post-operative scans of the final re-
cruited participants.
Recruitment
All patients referred to the HPB multidisciplinary
teams at each clinical site who are being considered
for liver resection or TACE based on local NHS
clinical care pathways will be eligible to participate.
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After an initial approach by a member of the direct
clinical care team, interested patients will be con-
tacted by a member of the research team by letter
explaining the purpose and requirements of the study,
and asked if they would like to participate. They will
be invited to an initial screening appointment at
which they can discuss the research further with the
investigators and their eligibility to take part in the
study will be confirmed.
Inclusion criteria
Male or female adult patients being considered for liver re-
section or TACE (for primary or secondary liver lesions).
Exclusion criteria
The following exclusion criteria will be adhered to:
i. Patients under the age of 18 years.
ii. Prisoners.
iii. Persons unable to have an MRI scan (including but
not limited to claustrophobia, implanted metallic
devices, metal foreign body)
iv. Adults with incapacity to provide informed consent
v. Non-provision of consent
Participants
Consent
Potential participants will be identified as above. A member
of the direct clinical care team looking after that patient (for
example surgeon, oncologist, nurse specialist, GP) will make
the initial contact with the patient in person or by phone
(or post) and ask whether they are willing to be approached
by the research team to consider participation. Those indi-
viduals who wish to consider participating will be sent an
invitation letter and participant information sheet and in-
vited to attend for a face-to-face meeting with a member of
the research team where they will have the opportunity to
ask questions before giving written informed consent and
being recruited into the study. Recruitment and informed
consent will be performed by the investigator/clinical re-
search nurse. It will be made clear that the individual may
withdraw from the study at any time without giving a rea-
son and with no consequence to their current or future
care. In addition, consent will be obtained to inform each
participant’s GP and the Consultant in charge of their care.
Patient decision period
Potential participants who have been invited to participate
will be given a period of up to 2 weeks (minimum 24 h) to
read the relevant information sheets, to contact a member
of the study team to get further information and ask
Fig. 1 Timelines for participant visits for both the main cohort and the two nested cohorts (chemotherapy/portal vein embolization (PVE))
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questions, before they are invited to attend for a conversa-
tion and commence the process of fully-informed consent.
Withdrawal of participants
Participants will be withdrawn from the clinical research
study in the following circumstances:
i. In cases of withdrawal of informed consent, where
capacity to provide such consent exists.
ii. In cases of withdrawal of consent by the patient’s
representative for adults who develop incapacity to
continue to provide informed consent during the
period of the study, for example due to critical illness.
Participants who wish to withdraw from the study will
be given the option to permit ongoing use of data and
samples which have already been collected, and/or fu-
ture recording and usage of routinely collected clinical
data and results. This will be clearly documented on the
patient consent form.
Measurements
Primary endpoint
To determine the ability of LiverMultiScan™to predict risk
of post-operative morbidity and mortality by measuring
the correlation between the pre-operative liver health as-
sessment score (HepaT1ca score - calculated by weighting
future remnant liver volume by liver inflammation and fi-
brosis (LIF) score) and the post-operative liver function
composite integer-based risk (Hyder-Pawlik) score [12].
Secondary endpoints
 To compare LiverMultiScan™image interpretations
with clinical outcomes after surgery or TACE in three
domains: post-operative liver function, surgery-specific
complication rate, and overall complication rate. The
Clavien-Dindo classification (using all 5 grades) of
morbidity will be used, in addition to free text descriptors
of complications. Morbidity and mortality at 30 days and
90 days after surgery will be reported.
 To compare LiverMultiScan™image interpretations
with histological findings in the resected liver
specimen in four domains: fibrosis, inflammation, fat
content and iron load
 To evaluate LiverMultiScan™image interpretations
correlated with post-operative length of stay
 To evaluate LiverMultiScan™interpretations in the
liver regeneration phase
 To identify prognostic biomarkers of liver health
 To evaluate whether LiverMultiScan™can add
information as to the type of liver tumour
 To evaluate biliary pathology after chemotherapy
and biliary regeneration after surgery with
quantitative MRCP
Summary of clinical data to be collected
A full set of the data fields being collected has been
exported from the data collection tool and is provided as
Additional file 1.
At initial visit:
1. Demographic and general clinical background
information,
2. Information regarding the primary liver lesion, and
if liver metastases, information regarding the
primary tumour,
3. Information relevant to background liver disease/
function,
4. Information regarding the proposed surgery/
intervention.
At interim visit: (in those having a second pre-operative
scan after a period of adjuvant (to the colon primary),
neoadjuvant or downstaging chemotherapy; or after PVE):
5. Information regarding the interim therapy received
including adverse effects and complications.
At operation/TACE:
6. Details of surgery/TACE procedure, including
weight of resected specimen.
At post-op visit:
7. Information regarding recovery from surgery or
TACE procedure, including complications and
post-op liver function.
Peripheral venous blood sampling
Blood samples will be obtained from each study partici-
pant on each visit and at the time of surgery for multiple
routine and specialist assays, including genetic analysis on
a maximum of four occasions over the course of the study.
MR imaging
A multiparametric MRI scan will be performed at each
visit to measure lipid, iron load, and fibroinflammatory
disease in the liver according to protocols in development
at Perspectum Diagnostics Ltd. and undertaken at CRIC
(Clinical Research Imaging Centre, QMRI, University of
Edinburgh/Royal Infirmary of Edinburgh), or at Basing-
stoke and North Hampshire Hospital Department of Radi-
ology. No intravenous contrast agents are used in
LiverMultiScan™scans. For routine clinical care Primovist™
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MRI will be performed subsequently at the same visit or
on a separate occasion. The total duration of LiverMultiS-
can™research scans will be approximately 30 min.
Tissue sampling from the resected specimen
Tissue samples will be taken from liver resection specimens.
Strict care will be taken not to compromise direct clinical
care pathology reporting. Samples will include fresh and
snap-frozen Tru-cut biopsies of the tumour and background
liver parenchyma and formalin-fixed paraffin-embedded
blocks of background liver and tumour tissue.
Samples of fresh background and tumour tissue will
be analysed for standard laboratory assays, including for
example for cell analysis, protein and gene expression,
and will be subject to more advanced analyses e.g. inte-
grative multiomics (including DNA and RNA sequen-
cing, metabolomics and proteomics). Fresh liver tissue
may be disrupted for primary cell cultures including for
the development of in vitro assays, immortalized cell
lines and organoids.
Samples of fixed background and tumour tissue will be
analysed using histological and immunohistochemical tech-
niques, but may also be subject to advanced analyses e.g. tis-
sue expression mapping should protocols develop to allow
this on fixed tissue in the future. Histology will be inde-
pendently scored by a second observer. Tissue samples may
be stored for at least 5 years from the date of collection.
Data analysis plan
Standard statistical and data analysis packages, including
R (Bell Laboratories, USA), MATLAB (MathWorks, USA)
and Python (Python Software Foundation, USA) will be
used. Evaluation of the novel diagnostic technologies will
be performed according to the STARD framework (http://
www.equator-network.org/reporting-guidelines/stard).
Primary endpoint
To determine ability of LiverMultiScan™ to predict risk of
post-operative morbidity and mortality by measuring the
correlation between the pre-operative liver health assess-
ment score and the post-operative risk score.
This analysis will measure the correlation between two
continuous variables. The first variable will be the FLR
volume weighted by the liver inflammation and fibrosis
(LIF) score. This weighting will effectively decrease the
FLR with increasing LIF score. The second variable will
be the composite post-operative risk score as defined
by Hyder and colleagues [12]. The distribution of both
variables will be tested for Normality (e.g., with the
Kolmogorov-Smirnov test) and the correlation calcu-
lated with the appropriate test (e.g., Pearson correlation
if Normally-distributed; Spearman’s rank correlation if
not, or non-linearly correlated).
Secondary endpoints
i) To compare LiverMultiScan™ image interpretations
with clinical outcome after surgery in three domains:
post-operative liver function, surgery-specific
complication rate and overall complication rate.
This analysis will use a combination of statistical mod-
elling techniques (e.g. logistic regression) and machine
learning techniques (e.g., random forest and tensor flow)
to identify the combination of MRI-derived measure-
ments (e.g., LIF, proton density fat fraction, diffusion
measurements) that best predict post-operative liver
function, or classify patients based on complication rate.
Derived models will be cross-validated using leave-x-out
cross-validation to avoid over-fitting of the model and
improve applicability to external populations.
The performance of classification models will be quan-
tified by the area under the receiver operator curve
(AUROC) along with the sensitivity, specificity, positive
predictive value and negative predictive value for the
most appropriate operating point. The statistical signifi-
cance of any differences in MRI-derived measures of
liver health between the different classes will be deter-
mined using the most appropriate test based on the
Normality of the distributions and the number of groups
being compared (e.g., t-test if comparing two Normally-
distributed samples; ANOVA if comparing multiple
Normally-distributed samples; Kruskal Wallis if comparing
non-Normally-distributed samples). The performance of
the regression models will be quantified using the
appropriate correlation test (e.g., Pearson correlation if
normally-distributed; Spearman’s rank correlation if not,
or non-linearly correlated).
ii) To compare LiverMultiScan™ image interpretations
with histological findings in the resected specimen in
four domains: fibrosis, inflammation, fat content
and iron load.
iii) To evaluate LiverMultiScan™ image interpretations
with post-operative length of stay.
iv) To evaluate LiverMultiScan™ image interpretations
in the liver regeneration phase.
v) To identify additional biomarkers of liver health.
This analysis will use a combination of statistical mod-
elling techniques (e.g., logistic regression) and machine
learning techniques (e.g., random forest and tensor flow)
to identify those clinical and image-derived parameters
being collected as part of the study that have utility in
predicting liver health.
vi) To evaluate whether LiverMultiScan™ can add
information as to the nature of the liver tumour.
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This endpoint will be evaluated using the same
analysis techniques described for the 1st secondary
endpoint above to identify and calculate the utility
of MRI-derived measurements for characterising liver
tumour tissue.
vii) To evaluate post-intervention cholangiopathy and
biliary regeneration with quantitative MRCP
This endpoint will use quantitative MRCP analysis
technology to characterise the regeneration of biliary
anatomy in the regenerating liver. This will be a descrip-
tive analysis evaluating the change in intra-hepatic bil-
iary volume, duct diameter and number of branches as
the liver regenerates.
Statistical analysis
Sample size
The sample size is pragmatic determined by the duration
of the study and recruitment rate. We estimate the fol-
lowing sample size n = 100 per site (n = 200 total) which
includes the nested cohort of n = 20 per site (n = 40
total). For the primary endpoint, this sample size would
allow us to detect a minimum correlation coefficient of
0.2 with a 5% level of significance and power of 80%
using a two-tailed test. Furthermore, this sample size will
support the evaluation of the secondary endpoints,
allowing us to account for any confounding factors (for
example, post-operative length of stay may be influenced
by lower discharge rates on weekends).
Benefit for participants
No direct benefit is expected for the participants. We en-
visage that the results of this study will benefit other pa-
tients being considered for liver surgery in the future, by
developing new technology which improves patient safety,
and society as a whole by advancing scientific knowledge
of using imaging to quantify liver health. We believe that
this study may lead to improvements in pre-operative
planning which will prevent or ameliorate the impact of
liver surgery for cancer. This will help to maximise the
health, and life expectancy, of patients with liver cancers.
Potential risks and burdens for research participants
The participants will be subjected to peripheral venous
blood sampling which may cause discomfort or pain.
MRI scans are not expected to pose a risk to patients, in
the absence of known contraindications. Patients will be
assessed prior to the scan for any potential contraindica-
tions to the procedure such as mechanical heart valves,
pacemakers, metallic prostheses and cochlear implants.
Dissemination
Results of the study will be presented at local, national and
international medical meetings. The findings of the study
will be published in peer reviewed medical/scientific jour-
nals and made open access on acceptance. If appropriate
the results of the study will be disseminated by press re-
leases by University of Edinburgh, Basingstoke and North
Hampshire Hospital or Perspectum Diagnostics. Informa-
tion may also be disseminated to the general public via
public engagement and community outreach programmes.
Discussion
Liver function can be regarded as the product of the
total volume of hepatocytes and the health of those he-
patocytes. After hepatectomy, a minimum level of liver
function is necessary for survival. At present, that pro-
jected liver function is based almost entirely on the esti-
mated FLR volume [13, 14], with most surgical teams
adopting minimum thresholds for FLR of approximately
25% in normal livers, and 40% in cirrhotic livers [15].
Ideally, projected future liver function should be calcul-
able as the product of the FLR volume and a continuous
variable measure of hepatocyte function. At present, as-
sessment of the FLR relies on computed tomography
(CT) volumetric measurement combined with a crude
estimate of hepatocyte function based on clinical judg-
ment and gleaned from surrogate markers of liver func-
tion based on blood tests. Liver fat content (steatosis)
can be measured on CT, or more accurately with mag-
netic resonance imaging (MRI) [16]. However, hepatic
fibroinflammatory disease, which has been shown to
correlate with overall and liver-related morbidity after
resection [17], typically requires an invasive biopsy to
diagnose accurately. Therefore, a preoperative non-invasive
investigation that provides the estimated FLR and a
validated measure of hepatocyte performance will be an
important advance in the safety assessment of patients
considering liver surgery.
Additional file
Additional file 1: HepaT1ca study list of data fields as a database export.
(PDF 67 kb)
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